Karyopharm Therapeutics
KPTI
KPTI
137 hedge funds and large institutions have $145M invested in Karyopharm Therapeutics in 2023 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 43 increasing their positions, 41 reducing their positions, and 22 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
0.38% less ownership
Funds ownership: 5.15% → 4.77% (-0.38%)
57% less capital invested
Capital invested by funds: $340M → $145M (-$195M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Holders
137
Holding in Top 10
–
Calls
$613K
Puts
$242K
Top Buyers
| 1 | +$4.41M | |
| 2 | +$4.26M | |
| 3 | +$3.17M | |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.11M |
| 5 |
Millennium Management
New York
|
+$2.04M |
Top Sellers
| 1 | -$14.3M | |
| 2 | -$6.3M | |
| 3 | -$3.55M | |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$3.26M |
| 5 |
Barclays
London,
United Kingdom
|
-$3.12M |